Literature DB >> 30789657

Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.

Bastien Nguyen1,2, Isabelle Veys3, Sophia Leduc1,4, Yacine Bareche1, Samira Majjaj1, David N Brown5, Bram Boeckx6,7, Diether Lambrechts6,7, Christos Sotiriou1, Denis Larsimont8, Christine Desmedt1,4.   

Abstract

Although invasive ductal breast cancer (IDC) represents the most common histological type of breast cancer, minor subtypes exist such as mucinous breast cancer (MuBC). MuBC are distinguished by tumor cells floating in extracellular mucin. MuBC patients are generally older and associated with a favorable prognosis. To unravel the molecular architecture of MuBC, we applied low-pass whole-genome sequencing and microscopic evaluation of stromal tumor infiltrating lymphocytes to 30 MuBC from a retrospective institutional cohort. We further analyzed two independent datasets from the International Cancer Genomics Consortium and The Cancer Genome Atlas. Genomic data (n = 26 MuBC, n = 535 estrogen receptor [ER] positive/HER2-negative IDC), methylation data (n = 28 MuBC, n = 529 ER-positive/HER2-negative IDC), and transcriptomic data (n = 27 MuBC, n = 467 ER-positive/HER2-negative IDC) were analyzed. MuBC was characterized by low tumor infiltrating lymphocyte levels (median = 0.0%, average = 3.4%, 95% confidence interval = 1.9% to 4.9%). Compared with IDC, MuBC had a lower genomic instability (P = .01, two-sided Mann-Whitney U test) and a decreased prevalence of PIK3CA mutations (39.7% in IDC vs 6.7% in MuBC, P = .01 in the International Cancer Genomics Consortium; and 34.8% vs 0.0%, P = .02 in The Cancer Genome Atlas, two-sided Fisher's exact test). Finally, our report identifies aberrant DNA methylation of MUC2 as a possible cause of extracellular production of mucin in MuBC.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 30789657     DOI: 10.1093/jnci/djz023

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

1.  Breast cancer histologic subtypes show excess familial clustering.

Authors:  N Lynn Henry; Lisa A Cannon-Albright
Journal:  Cancer       Date:  2019-05-23       Impact factor: 6.860

Review 2.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

Review 3.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

4.  Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer.

Authors:  Hyun Ee Yim; Jang-Hee Kim; Mi Sun Ahn; Yongsik Jung; Jin Roh; So Hyun Park; Tae-Gyu Kim; Jin-Hyuk Choi; Seok Yun Kang
Journal:  Front Oncol       Date:  2021-03-01       Impact factor: 6.244

5.  The genomic landscape of carcinomas with mucinous differentiation.

Authors:  Bastien Nguyen; Francisco Sanchez-Vega; Christopher J Fong; Walid K Chatila; Amir Momeni Boroujeni; Fresia Pareja; Britta Weigelt; Christos Sotiriou; Denis Larsimont; Jorge S Reis-Filho; Christine Desmedt; Nikolaus Schultz
Journal:  Sci Rep       Date:  2021-05-04       Impact factor: 4.379

6.  Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.

Authors:  Fresia Pareja; Mahsa Vahdatinia; Caterina Marchio; Simon S K Lee; Arnaud Da Cruz Paula; Fatemeh Derakhshan; Edaise M da Silva; Pier Selenica; Higinio Dopeso; Sarat Chandarlapaty; Hannah Y Wen; Anne Vincent-Salomon; Edi Brogi; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Clin Pathol       Date:  2020-11-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.